Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Gut

• Publication date

  2015-09-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1136/gutjnl-2015-309600PMID 26385087
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats.

  2015cited by this paper
• Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension

  2015cited by this paper
• Angiotensin‐II type 1 receptor‐mediated Janus kinase 2 activation induces liver fibrosis

  2014cited by this paper
• Future therapy of portal hypertension in liver cirrhosis – a guess

  2014cited by this paper
• KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins

  2014cited by this paper
• Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis.

  2013cited by this paper
• Evolving therapies for liver fibrosis.

  2013cited by this paper
• Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology

  2013cited by this paper
• Angiotensin signalling in pulmonary fibrosis.

  2012cited by this paper
• HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.

  2012cited by this paper
• JAK2 the future: therapeutic strategies for JAK-dependent malignancies.

  2012cited by this paper
• Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction

  2011cited by this paper
• The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure

  2010cited by this paper
• Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

  2010cited by this paper
• Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status

  2010cited by this paper
• Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells.

  2010cited by this paper
• A novel model of CCl4-induced cirrhosis with ascites in the mouse.

  2009cited by this paper
• Role of β3‐adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis

  2009cited by this paper
• Mechanisms of extrahepatic vasodilation in portal hypertension

  2008cited by this paper
• Mechanisms of hepatic fibrogenesis.

  2008cited by this paper
• Novel aspects of the renin-angiotensin-aldosterone-system.

  2008cited by this paper
• Vascular dysfunction in human and rat cirrhosis: Role of receptor‐desensitizing and calcium‐sensitizing proteins

  2007cited by this paper
• Both Ca2+ -dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine.

  2007cited by this paper
• Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho‐kinase and activation of endothelial nitric oxide synthase

  2007cited by this paper
• Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats

  2007cited by this paper
• Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis

  2006cited by this paper
• Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats.

  2006cited by this paper
• Vascular, hemodynamic and renal effects of low‐dose losartan in rats with secondary biliary cirrhosis

  2005cited by this paper
• Liver fibrosis.

  2005cited by this paper
• Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

  2004cited by this paper
• NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis.

  2003cited by this paper
• Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats

  2003cited by this paper
• The world health report 2002 - reducing risks, promoting healthy life.

  2003cited by this paper
• The world health report 2002 - reducing risks, promoting healthy life.

  2003cited by this paper
• [Mechanisms of hepatic fibrogenesis].

  2002cited by this paper
• Complications of cirrhosis. I. Portal hypertension.

  2000cited by this paper
• Angiotensin II induces contraction and proliferation of human hepatic stellate cells.

  2000cited by this paper
• Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop

  1997cited by this paper

• Evaluation of a 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet-induced mouse model in a comparative experimental study of portal hypertension

  2026cites this paper
• miRNAs and Alcohol-Related Hepatitis

  2025cites this paper
• Interaction of inflammation and portal hypertension in cirrhosis progression

  2025cites this paper
• Qishen Yiqi alleviates periostin-mediated cardiac fibrosis and hypertrophy in Dahl hypertensive rat hearts and angiotensin II-induced cardiac organoids

  2025cites this paper
• Multiparametric MRI Including T1ρ Mapping for Hepatic Fibrosis Assessment in Preclinical Models of Steatotic Liver Disease.

  2025cites this paper
• From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension

  2025cites this paper
• The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells

  2023cites this paper
• Emerging Therapeutic Targets for Portal Hypertension

  2023cites this paper
• Navigating Nonalcoholic Fatty Liver Disease (NAFLD): Exploring the Roles of Estrogens, Pharmacological and Medical Interventions, and Life Style.

  2023cites this paper
• Mechanotransduction-induced glycolysis epigenetically regulates a CXCL1-dominant angiocrine signaling program in liver sinusoidal endothelial cells in vitro and in vivo.

  2022cites this paper
• Liver Fibrosis—From Mechanisms of Injury to Modulation of Disease

  2022cites this paper
• Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications

  2022cites this paper
• Current and investigational drugs in early clinical development for portal hypertension

  2022cites this paper
• Characteristics of myeloproliferative neoplasm-associated portal hypertension and endoscopic management of variceal bleeding

  2022cites this paper
• Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

  2022influential citation
• The role of JAK inhibitors in hematopoietic cell transplantation

  2022cites this paper
• Disruption of myofibroblastic Notch signaling attenuates liver fibrosis by modulating fibrosis progression and regression

  2021cites this paper
• Study on the effect of Mongolian medicine Qiwei Qinggan Powder on hepatic fibrosis through JAK2/STAT3 pathway.

  2021cites this paper
• Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD

  2021cites this paper
• Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1

  2021cites this paper
• Intercellular crosstalk regulating ARRB2/RARRES1 is involved in transition from fibrosis to cancer

  2021cites this paper
• TAFRO syndrome complicated by porto-sinusoidal vascular liver disease with portal hypertension: a case report

  2021cites this paper
• Extrahepatic Surgery in Cirrhosis Significantly Increases Portal Pressure in Preclinical Animal Models

  2021cites this paper
• Extracellular Matrix Remodeling in Chronic Liver Disease

  2021cites this paper
• Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy

  2021cites this paper
• Role of extracellular vesicles in liver diseases and their therapeutic potential.

  2021cites this paper
• Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis

  2021cites this paper
• Ursolic acid reverses liver fibrosis by inhibiting interactive NOX4/ROS and RhoA/ROCK1 signalling pathways

  2020cites this paper
• Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis

  2020cites this paper
• Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview

  2020cites this paper
• Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats

  2020influential citation
• Combination of phosphodiesterase‐5‐inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction

  2020cites this paper
• Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension

  2020cites this paper
• Regulation of hepatic stellate cell contraction and cirrhotic portal hypertension by Wnt/β‐catenin signalling via interaction with Gli1

  2020cites this paper
• Study on the effect of Mongolian Medicine Qiwei Qinggan 1 Powder on Hepatic Fibrosis through JAK2/STAT3 Pathway 2

  2020cites this paper
• Practical Methods for Liver Cell Biology

  2020cites this paper
• Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with my- eloproliferative neoplasms

  2019cites this paper
• Novel Targets and Drug Development in Portal Hypertension

  2019cites this paper
• SIRT1 inhibits gastric cancer proliferation and metastasis via STAT3/MMP‐13 signaling

  2019cites this paper
• Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats

  2019cites this paper
• Interaction Mechanisms Between the NOX4/ROS and RhoA/ROCK1 Signaling Pathways as New Anti- fibrosis Targets of Ursolic Acid in Hepatic Stellate Cells

  2019cites this paper
• TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor

  2019cites this paper
• Anatomy of rodent and human livers: What are the differences?

  2019cites this paper
• TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis in vivo

  2019cites this paper
• Quantification of Liver Fibrosis at T1 and T2 Mapping with Extracellular Volume Fraction MRI: Preclinical Results.

  2018cites this paper
• Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease

  2018cites this paper
• Animal Models When Examining the Gut-Liver Axis

  2018cites this paper
• Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon

  2018cites this paper
• Managing portal hypertension in patients with liver cirrhosis

  2018cites this paper
• Research progress on signaling pathways in cirrhotic portal hypertension

  2018cites this paper
• Influence of genetic variations in the SOD1 gene on the development of ascites and spontaneous bacterial peritonitis in decompensated liver cirrhosis

  2017cites this paper
• Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close?

  2017cites this paper
• Portal Vein Thrombosis and Cirrhosis: The Role of Anticoagulation

  2017cites this paper
• Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts

  2017cites this paper
• Therapeutic pro-fibrogenic signaling pathways in fibroblasts.

  2017cites this paper
• Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial

  2017cites this paper
• Novel treatment options for portal hypertension

  2017cites this paper
• ACE2 and the Homolog Collectrin in the Modulation of Nitric Oxide and Oxidative Stress in Blood Pressure Homeostasis and Vascular Injury

  2017cites this paper
• Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B

  2017cites this paper
• Expression of muscarinic acetylcholine receptors in hepatocytes from rat fibrotic liver.

  2017cites this paper
• Hepatic stellate cells as key target in liver fibrosis.

  2017cites this paper
• Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice*

  2017cites this paper
• Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension.

  2017cites this paper
• Emergency TIPS in a Child-B patient : When opens and when closes the window of opportunity ?

  2016cites this paper
• Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis

  2016cites this paper
• Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis

  2015cites this paper